ABSTRACT Patients with left ventricular thrombi not caused by recent myocardial infarction were prospectively studied by indium-1 1 1 platelet imaging and two-dimensional echocardiography to determine the reproducibility of these techniques and the short-term effects of sulfinpyrazone (200 mg four times daily), aspirin (325 mg three times daily) plus dipyridamole (75 mg three times daily), and fulldose warfarin. At baseline, all patients underwent indium-1 1 1 platelet imaging and echocardiography, and the results were positive for thrombus. In six patients on no antithrombotic drug therapy, repeat platelet scans and echocardiographic studies at 6.0 3.3 weeks remained positive and were unchanged. In seven patients studied on sulfinpyrazone, three platelet scans became negative, two became equivocal, and two were unchanged; the presence and size of thrombus was constant by echocardiography in all seven patients. Of the six patients studied on aspirin plus dipyridamole, one platelet scan became negative, those of three became equivocal, and two were unchanged; all echocardiographic findings remained positive, but one patient had decreased thrombus size. Among four warfarin-treated patients, three had resolution of platelet deposition and one was unchanged; by echocardiography, thrombus resolved in one patient, was decreased in size in one, and was unchanged in two. We conclude that, in the absence of antithrombotic drug therapy, platelet imaging and echocardiographic findings are stable in patients with left ventricular thrombi not caused by recent myocardial infarction. Sulfinpyrazone, aspirin plus dipyridamole, and warfarin all interrupt platelet deposition in some patients with chronic left ventricular thrombi. The hematologic activity of ventricular thrombus, i.e., the extent of ongoing platelet incorporation, may be inhibited by short-term drug therapy without significant changes in echocardiographically measured thrombus size. Circulation 69, No. 3, 561-568, 1984. PATIENTS with left ventricular mural thrombi are at risk for systemic embolism.'1- However 
PATIENTS with left ventricular mural thrombi are at risk for systemic embolism.'1-However, appropriate identification of and therapy for such patients remain uncertain, largely because reliable methods of thrombus detection during life have not been previously available. Two recently developed noninvasive techniques, indium-1 1 platelet imaging 16 17 and two-dimensional echocardiography, 13^1 4, 1623 can now be used for the diagnosis of thrombi and for the assessment of antithrombotic drug therapy. These two methods of thrombus detection offer distinctly different patho-physiologic information. Platelet imaging, which detects ongoing platelet deposition on the thrombus surface, can estimate left ventricular thrombus activity; echocardiography, which produces anatomic images of thrombi, can estimate thrombus size. Thrombus resolution after anticoagulation with warfarin has been shown after acute myocardial infarction. 22 However, the effects of warfarin, which inhibits fibrin deposition, have not been studied in patients with left ventricular thrombi present for months to years after myocardial infarction. The frequent detection of platelet deposition by indium-1 1 1 platelet imaging in such patients implies that ventricular thrombus formation is also partially dependent on platelet mechanisms. 6 17 The effects of platelet inhibitors on left ventricular thrombi have not been prospectively evaluated. Unlike warfarin, these drugs are quite safe and are easily administered.
The purposes of this study were to define the reproducibility of platelet imaging and echocardiography for the detection of left ventricular thrombi in patients without recent myocardial infarction and to prospectively determine the effects of short-term antithrombotic drug therapy by these noninvasive techniques. Our results suggest that platelet inhibitors or warfarin inhibit left ventricular thrombus activity in some patients and that platelet imaging is more likely than echocardiography to detect short-term drug effects.
Methods
Subjects. Sixteen patients with left ventricular thrombi were prospectively studied to determine the reproducibility of results from platelet imaging and echocardiographic examination and the short-term effects of sulfinpyrazone, aspirin plus dipyridamole, or results in a total dose to the body of approximately 0.3 to 0.9 rad, a dose to the liver of 0.6 to 2.5 rad, a dose to the spleen of 25 to 34 rad, and a dose to the male gonads of 0.1 to 0.5 rad.2 29 Anterior, 45 degree left anterior oblique, and left lateral images were obtained for 300,000 counts/view at 48, 72, and 96 hr after labeled-platelet injection with a Sigma 410 Ohio Nuclear Gamma Scintillation Camera with a medium-energy parallelhole collimater. Both gamma photon peaks of indium-I 11 (173 and 247 keV) were counted and recorded on Polaroid trilens film. Unprocessed platelet images were interpreted by two blinded observers who were unaware of the study sequence. A study result was defined as positive for thrombus when a discrete area of intracardiac activity clearly greater than the background blood pool was present in at least two of the three views.
Results were defined as equivocal when the area of presumed THERAPY AND PREVENTION-VENTRICULAR THIROMBI abnormal platelet deposition was seen in one or more views anid was only slightly greater than the adjacent intracardiac blood pool. A result was considered negative when no views had a localized area of increased uptake. There was one disagreement that was resolved by consensus. Drug inhibition of platelet deposition was defined as conversion of a positive result to negative or equivocal. lntraobscrver reproducibility of this method was assessed by blinded repetitive analysis of 25 studies by one observer 8 months later. On initial interpretation, 11 results were positive, three were equivocal, and iI were negative. The repeat analysis was the same in 22 of 25 (88)) studies.
In three studies, the second analysis was different (equivocal to negative in one, negative to equivocal in one, and positive to equivocal in one). Interobserver reproducibility was tested by having a second investigator analyze the results of the samc 25 studies. The two observers were in agreement in all cases. Thus, the methods of visual analysis were considered reproducible.
Two-dimensional echocardiography. Two-dimensionial echocardiograms were obtained during each platelet study with a phased-array wide-angle sector scannei (Toshiba Medical Systems: Tokyo), and the results were blindly inter-preted as positive, negative, or equivocal fbi-left ventricular thrombus by previously defined criteria.14 We estimated rnaximnal left vyentricular thrombus thickness in millimeters in an apical view by measuring perpendicular to the underlying myocardium frorm the presumed endocardial echo to the thrombus-blood interface. using a calibration scale displayed with each image. Although the thrombus and underlying myocardium often have similar echo densities, an interface was often detectable by the use of multiple gain and reject settings; when this interface could not be detected, the measurement was made to the epicardial-pericardial interface. Similar views were measured on each serial study.
To assess the intraobserver reproducibility of this measurement, 21 echocardiograms were blindly reanalyzed by one observer 4 to 14 days apart. For intraobserver reproducibility, the correlation coefficient between the first analysis (mean thick- 
three patients. StuLdy results were interpreted by one observer without knowledge of any clinical characteristics or the study sequence. In 18 patients, thrombus thickness neither increased nor decreased greater than 5 mm on serial study (mean thickness 1.8 +-0.8 vs 1.7 ± 0.7 cm, p = NS by paired t testing). In one patient, thrombus thickness increased 0.6 cm in a study performed 4 months later, and in onie patient studied 2 weeks apart, the result of the second echocardiographic examination was interpreted as being only equivocal for thrombus. Thus, the measurement of thrombus thickness over time in patients without recent myocardial infarctioni who did not receive heparin or warfarin was reproducible over the period of study. To account for the intraobserver and temporal variation in the measuremenit of thrombus thickness, we defined a reduction in thrombus size as either complete thrombus resolution or a >5 mm reduction in thronibus thickness. This cut off appeared reasonable, since in the intraobserver reprioducibility study, only one of the 21 studies showed mnore than a 5 mm difference on repeat analysis. Additionally, in the temporal reproducibility study, only one of 20 thrombi decreased in size by more than 5 mm during follow-up.
Results
For all six patients who underwent baseline and repeat studies on no antithrombotic drugs, results remained positive by platelet imaging and there was no change in thrombus size by echocardiography ( figure  1) . Of the seven patients who had serial studies before and during sulfinpyrazone therapy, none showed any change in thrombus size by echocardiography (table  1) . Five of these patients, however, had inhibition of platelet deposition as shown by platelet imaging; in three, the result of the platelet scan became negative (figure 2), and in two the result of the scan became equivocal. In two patients, deposition was unchanged during sulfinpyrazone therapy. 24 and since the embolic risk is highest then. 310 The susceptibility to antithrombotic medications may differ between freshly formed and chronic thrombi. In this regard, a preliminary echocardiographic study of patients less than 5 weeks after infarction showed thrombus reduction or resolution in four of 10 patients treated with sulfinpyrazone (400 mg twice a day). 2 We chose sulfinpyrazone as the primary study drug since it appeared to inhibit platelet deposition in a similar model of arterial thrombosis in two of four patients with thrombi in abdominal aortic aneurysms. 25 Additionally, in randomized studies, sulfinpyrazone reduced the incidence of arteriovenous shunt thromboSiS33 and decreased the incidence of systemic embolism in patients with mitral stenosis, presumably by decreasing left atrial thrombus formation.34 In contrast.
we have not found sulfinpyrazone effective in decreasing platelet deposition on Dacron arterial grafts in man,35 possibly because Dacron surfaces are a much more potent stimulus to platelet deposition. In the current study, sulfinpyrazone inhibited deposition in five of seven subjects with chronic thrombi during shortterm therapy (three results became negative and two became equivocal) without affecting thrombus size. allow a more precise quantitative evaluation of both thrombus activity and size. Another limitation concerns the sensitivity and reproducibility of indium-1 1 1 platelet imaging for detection of left ventricular thrombus. In the only study assessing sensitivity, platelet imaging detected 10 of 14 (71%) patients with proven thrombi.'7 Since the sensitivity of platelet imaging is not 100%, a high degree of reproducibility is essential if platelet imaging is to be used to evaluate the effects of therapy. Although our results of platelet imaging were reproducible in six patients restudied on no antithrombotic medications, additional reproducibility studies are desirable. We have previously documented that findings from platelet imaging in patients with Dacron arterial grafts are reproducible. 39 This study was not designed to assess a clinical end point, such as reduction in embolic events. Hence, no conclusions can be reached as to the potential clinical significance of our findings in an individual patient, since it remains to be proven whether platelet deposition or its inhibition predicts subsequent embolization. Additionally, longer-term studies that use platelet inhibitors in a larger number of patients are required to determine if such drugs alone can lead to thrombus resolution as assessed by echocardiography.
Implications. Both platelet imaging and echocardiography can measure antithrombotic drug effects in patients with left ventricular thrombi. During short-term therapy with platelet inhibitors, platelet deposition can be inhibited without an identifiable change in thrombus size. Determination of the clinical and long-term importance of these discordant observations awaits further study. However, these findings suggest that the earliest evidence of drug effect may be demonstrated by platelet imaging and that echocardiography may not be a reliable indicator of short-term drug activity. These findings were obtained in patients with remote myocardial infarction whose thrombi were chronic. More rapid changes in thrombus mass might be found in more recently formed thrombi, such as those associated with acute myocardial infarction.
